NCT07199855View on ClinicalTrials.gov

Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

June 1, 2027

Study Completion Date

July 1, 2029

Conditions

B-Cell Acute Lymphoblastic Leukemia, Adult

Interventions

DRUG

blinatumomab combined with venetoclax as maintenance therapy

blinatumomab combined with venetoclax as maintenance therapy for high-risk Philadelphia chromosome-negative acute B-cell lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem cell transplantation

Trial Locations (1)

310000

First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors

lead

Zhejiang University

OTHER